Finance Watch: OS Therapies Raises $6.4m In Year’s 14th Biopharma IPO In The US
Verastem Grosses $55m For Future Commercial Efforts
Public Company Edition: OS Therapies launched this year’s smallest initial public offering, to fund its lead program in osteosarcoma. Also, Australian firm Telix, after opting out of a US IPO, grossed A$650m ($425.5m) from investors at home. Day One raised $175m in a private placement.
